Format

Send to

Choose Destination
See comment in PubMed Commons below
J Clin Pharmacol. 2012 Dec;52(12):1918-26. doi: 10.1177/0091270011430506. Epub 2012 Jan 10.

Population pharmacokinetics of rituximab in patients with chronic lymphocytic leukemia.

Author information

1
Clinical Pharmacology, MS 463a, Genentech Inc, 1 DNA Way, South San Francisco, CA 94080, USA. li.jing@gene.com

Abstract

This retrospective analysis characterizes rituximab population pharmacokinetics in combination with fludarabine and cyclophosphamide and its effect on fludarabine and cyclophosphamide disposition in chronic lymphocytic leukemia (CLL) patients. Rituximab concentration data were well described by a 2-compartment model comprising a time-varying clearance component related to the target-mediated clearance pathway and a constant clearance component reflecting catabolic elimination pathway. Marked differences were observed compared to pharmacokinetic parameters for non-Hodgkin lymphoma (NHL) obtained previously: in CLL, time-varying clearance at time zero (CL(2)) was faster, volumes of distribution (V(1) and V(2)) were larger, and rate of change (K(des)) from the targetmediated clearance pathway to catabolic elimination was lower than NHL. Fludarabine and cyclophosphamide disposition showed no apparent change when co-administered with rituximab. A positive correlation between pharmacokinetic parameters and clinical response was observed, supporting the use of the higher rituximab dose of 500 mg/m(2) in CLL patients (vs 375 mg/m(2) in NHL) to achieve an effective clinical response.

PMID:
22235140
DOI:
10.1177/0091270011430506
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center